ArticleJournal of experimental & clinical cancer research : CR2026
NRGN inhibits CD8⁺ T cell effector function by downregulating MHC-I expression through the FMR1-IRF8 axis in hepatocellular carcinoma.
Article in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundNeurogranin (NRGN) has been extensively studied as a neuron-enriched synaptic regulatory protein, yet its function in cancer remains largely unexplored. Immune evasion driven by defective antigen presentation and CD8⁺ T cell dysfunction is a hallmark of hepatocellular carcinoma (HCC). This study aimed to determine whether NRGN contributes to immune escape in HCC and to elucidate its underlying molecular mechanism.
methodsNRGN expression and clinical relevance were analyzed in public datasets and validated in HCC tissues. Transcriptomic and enrichment analyses assessed antigen presentation. Gain- and loss-of-function experiments were performed in human and murine HCC cells, while orthotopic and subcutaneous models with CD8⁺ T cell exhaustion, β2M knockout, and H-2Kb blockade evaluated immune dependence in vivo. RNA stability, RNA pulldown, RIP, co-immunoprecipitation, ubiquitination, and luciferase assays were conducted to define the molecular mechanisms.
resultsNRGN was significantly upregulated in HCC and associated with advanced stage and poor survival, correlating inversely with GZMB⁺ CD8⁺ T cell infiltration. NRGN knockdown enriched MHC-I antigen presentation pathways and restored MHC-I/β2M expression, tumor cell surface antigen presentation, and CD8⁺ T cell cytotoxicity. In vivo, NRGN silencing suppressed tumor growth and prolonged survival in a CD8⁺ T cell-dependent manner, effects reversed by β2m deletion or H-2Kb blockade. Mechanistically, NRGN downregulated IRF8 by reducing its mRNA stability through FMR1 and stabilizing FMR1 protein via inhibition of MYCBP2-mediated ubiquitination, thereby sustaining suppression of antigen presentation.
conclusionsNRGN suppresses antigen presentation via the FMR1-IRF8-MHC-I axis, thereby impairing CD8⁺ T cell-specific effector functions and promoting immune evasion in HCC. Modulation of the NRGN-IRF8-MHC-I axis could represent a potential strategy for improving immunotherapeutic responses.
Indexed as
Identifiers
42458540What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.